Anton A. Privalenko

Anton A. Privalenko

Auto-generated profile, based on publicly available information

Anton A. Privalenko

CentralResearch Institute of Epidemiology, Moscow, Russian Federation

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2024 in Epidemiology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
ATAnna E. Tsygankova
Anna E. Tsygankova
Vladimir ChulanovVladimir Chulanov
Vladimir Chulanov
AGAndrey Gerasimov
Andrey Gerasimov
EVElena V. Volchkova
Elena V. Volchkova
APAnton A. Privalenko
Anton A. Privalenko
БАБахтина Виктория Александровна
Бахтина Виктория Александровна
BACKGROUND: Today, clinicians and their decisions extensively rely on specific treatment algorithms. These algorithms include prognostic models to identify high risk patients requiring hospital admission and clinical monitoring. This study suggests a prognostic model for forecasting COVID-19 outcomes in patients with advanced HIV infection, considering the high risk of unfavorable outcomes and the need for a specialized approach. AIM: To develop a prognostic model that combines predictors of unfavorable COVID-19 outcomes in patients with advanced HIV infection. MATERIALS AND METHODS: The study was based on 500 medical records of patients with advanced HIV infection admitted for confirmed COVID-19 between March 1, 2020, and December 31, 2022, and inpatient treatment at the Infectious Diseases Hospital in Moscow. RESULTS: All 500 patients were evaluated for 167 predictive markers for unfavorable COVID-19 outcomes, outlining 50 indicators that significantly varied across the subgroups of patients with both advanced HIV infection and COVID-19 depending on the presence of favorable or poor outcomes. Oxygen therapy was the most significant factor showing a strong correlation with poor outcomes in patients with advanced HIV infection and COVID-19. Subsequently, predictors were selected stepwise to enhance the predictive accuracy of the resulting model by adding more factors. The resulting model included seven factors: oxygen therapy requirements, CD4+ count under 50 cells/μL; manifested CMV infection with lung damage; elevated levels of lactate dehydrogenase, urea, and fibrinogen; and the presence of unspecified encephalitis. Using the available data in the calculations, a prognostic scenario and a receiver operating characteristic (ROC) curve were created to assess the practical significance of the proposed prognostic model. The area under the ROC curve was 90.9%, confirming the prediction accuracy and overall practical significance of the model. CONCLUSIONS: The proposed prognostic model enables the assessment of potential outcomes and planning of adequate therapies in patients with HIV and COVID-19 co-infection admitted to hospitals at advanced stages of the disease.

13 January 2026 in Current HIV Research
Verified
Journal Article
Closed access
ATAnna E. Tsygankova
Anna E. Tsygankova
AGAndrey Gerasimov
Andrey Gerasimov
APAnton A. Privalenko
Anton A. Privalenko
AFAnastasia A. Fomicheva
Anastasia A. Fomicheva
KAKhazhar R. Aktulaeva
Khazhar R. Aktulaeva
EVElena V. Volchkova
Elena V. Volchkova
Background:: In their struggle with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, physicians are intensively focused on high-risk patient groups. One such group includes immunosuppressed people living with HIV (PLWH). This study considers the most vulnerable cohort of advanced HIV patients in order to identify potential risk factors for unfavorable SARS-CoV-2 disease (COVID-19) outcomes. Method:: This study analyzed data from a census-based sample of 500 patients. The sample en-compassed all consecutive patients during the study period (2020–2022) who met the inclusion and exclusion criteria. All selected patients, aged over 18 years, were hospitalized with confirmed advanced HIV and moderate to severe COVID-19 coinfection at the Infectious Disease Hospital (IDH) in Moscow from 2020 to 2022. Results:: The overall mortality rate reached 27.0% (135 deaths; 95% CI 23.3–30.9%). Primary analysis identified three key independent predictors of mortality: mechanical ventilation demon-strated the strongest association (aOR 4.29, 95% CI 3.15–5.84, p < 0.001), followed by profound immunosuppression (CD4+ counts below 50 cells/mm³; aOR 3.28, 95% CI 2.41–4.47, p < 0.001) and high HIV viral load exceeding 20,000 copies/mL (aOR 3.37, 95% CI 2.52–4.51, p = 0.003). Secondary outcomes revealed important clinical patterns: oxygen support requirements showed a graded mortality risk from low-flow systems (aOR 3.40, p < 0.001) to mechanical ventilation (aOR 4.29, p < 0.001), while newly diagnosed HIV patients faced significantly higher mortality (46.2%) compared to known HIV cases (24.6%). Opportunistic infections substantially worsened prognosis, particularly Kaposi's sarcoma (aOR 3.17, 95% CI 2.28–4.41, p < 0.001), pneumocystis pneumonia (aOR 2.74, 95% CI 1.98–3.79, p < 0.001), and CMV pneumonitis (aOR 2.56, 95% CI 1.85–3.54, p < 0.001). Protective factors included preserved immunity (CD4+ >500 cells/mm³; aOR 2.77, 95% CI 2.08–3.69, p = 0.03) and virological suppression (aOR 2.22, 95% CI 1.67–2.95, p = 0.001). Ferritin levels above 600 ng/mL emerged as an additional risk marker (aOR 1.73, 95% CI 1.32–2.27, p = 0.0006), though with less robust association than primary predictors. Conclusion:: These findings can provide physicians with a risk-based prioritization algorithm for patients with COVID-19 and advanced HIV coinfection. Identifying patients at highest risk for unfavorable outcomes ensures timely ICU admission, faster patient examination, and initiation of dedicated treatment.